News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Interpharm Holdings, Inc. (IPA) Announces Introduction Of A Female Hormone Product With First Year Revenue Of $11.5 Million


10/19/2005 5:10:47 PM

HAUPPAUGE, N.Y.--(BUSINESS WIRE)--July 18, 2005--Interpharm Holdings, Inc. (AMEX: IPA) today announced that it has completed the development of a female hormone product. This product, which requires a dedicated facility and specialized handling, will be exclusively distributed by Centrix Pharmaceutical, Inc. Pursuant to a multi-year contract, Centrix has committed to purchase $11.5 million of the product during the first year. Interpharm plans to commence shipment of the product within a month. This product marks the beginning of the execution of Interpharm's recently implemented four-year business plan. This plan will shift Interpharm's focus from commodity type products with gross margins typically in the low 20% range to significantly higher margin products.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES